心室中隔への植え込みに最適化されたLINEA心臓ペーシングリードの安全性と性能 (STARLIGHT)
心室中隔への移植に最適化されたLINEA心臓ペーシングリードの安全性と性能
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Antoine Guihard
- 電話番号:+33 1 46 01 33 20
- メール:antoine.guihard@cf.microport.com
研究場所
-
-
-
Novara、イタリア
- 募集
- Ospedale Maggiore della Carità - AO Univ.
-
コンタクト:
- Gabriele Dell'Era
- メール:gabriele.dellera@maggioreosp.novara.it
-
Pisa、イタリア
- 募集
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
コンタクト:
- Gianluca Mirizzi
- メール:gmirizzi@ftgm.it
-
-
-
-
-
Girona、スペイン
- 募集
- Hospital Universitari de Girona Doctor Josep Trueta
-
コンタクト:
- María Emilce Trucco
- メール:metrucco.girona.ics@gencat.cat
-
Granada、スペイン
- 募集
- Hospital Universitario Virgen de las Nieves
-
コンタクト:
- Manuel Molina
- メール:manuel.molina.lerma@gmail.com
-
Valencia、スペイン
- 募集
- Hospital Universitari i Politècnic La Fe
-
コンタクト:
- Óscar Cano
- メール:oscape13@hotmail.com
-
-
-
-
-
Annecy、フランス
- 募集
- Centre Hospitalier Annecy Genevois
-
コンタクト:
- Pierre Frey
- メール:pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand、フランス
- 募集
- CHU Clermont-Ferrand
-
コンタクト:
- Pierre-Antoine Catalan
- メール:pacatalan@chu-clermontferrand.fr
-
Grenoble、フランス
- 募集
- CHU Grenoble
-
コンタクト:
- Adrien Carabelli
- メール:acarabelli@chu-grenoble.fr
-
Montpellier、フランス
- 募集
- Clinique du Millénaire
-
コンタクト:
- Nicolas Clémenty
- メール:nicolas.clementy@gmail.com
-
Rouen、フランス
- 募集
- CHU Rouen Hôpital Charles Nicolle
-
コンタクト:
- Raphaël Al Hamoud
- メール:raphael.al-hamoud@chu-rouen.fr
-
Tours、フランス
- 募集
- Hôpital Trousseau
-
コンタクト:
- Arnaud Bisson
- メール:a.bisson@chu-tours.fr
-
-
-
-
-
Ghent、ベルギー
- 募集
- Ghent University Hospital
-
コンタクト:
- Jan De Pooter
- メール:jadpoote.depooter@ugent.be
-
-
-
-
-
Coimbra、ポルトガル
- 募集
- ULS de Coimbra
-
コンタクト:
- João Ferreira
- メール:joaoaferreira29@gmail.com
-
Lisbon、ポルトガル
- 募集
- ULS Santa Maria
-
コンタクト:
- Nelson Cunha
- メール:nelsoncunha@campus.ul.pt
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LINEA 心臓ペーシングリード
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
LINEA lead complication free rate at 3 months
時間枠:3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
時間枠:3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
時間枠:3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
時間枠:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
時間枠:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
時間枠:Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
時間枠:Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
時間枠:Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
時間枠:Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
時間枠:3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
時間枠:18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
時間枠:1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
時間枠:1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
時間枠:1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
時間枠:1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
時間枠:1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。